Allen Capital Group’s Gilead Sciences GILD Stock Holding History

Allen Capital Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$334K	Buy	2,400 +112	+5%	+$15.7K	0.03%	225
2025 Q4	$281K	Buy	2,288 +119	+5%	+$14.5K	0.03%	235
2025 Q3	$241K	Buy	2,169 +184	+9%	+$20.9K	0.02%	242
2025 Q2	$220K	Buy	+1,985	New	+$211K	0.02%	252
2021 Q3	–	Sell	-3,007	Closed	-$207K	–	165
2021 Q2	$207K	Sell	3,007 -5,908	-66%	-$394K	0.04%	147
2021 Q1	$576K	Buy	8,915 +1,378	+18%	+$88.9K	0.13%	94
2020 Q4	$439K	Sell	7,537 -1,948	-21%	-$118K	0.11%	100
2020 Q3	$612K	Buy	9,485 +1,051	+12%	+$72.9K	0.15%	89
2020 Q2	$649K	Buy	+8,434	New	+$646K	0.17%	81

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Allen Capital Group's GILD Position: Q1 2026 in Review

Allen Capital Group increased its Gilead Sciences (GILD) stake by 4.9% in Q1 2026, buying an estimated $15.7K and bringing the position to 2,400 shares worth $334K. The position accounts for 0.03% of the portfolio, ranked #225.

Allen Capital Group first reported a position in GILD in Q2 2020 and has held it in 9 quarters since. The position peaked at $649K in Q2 2020. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Allen Capital Group held 2,400 shares of Gilead Sciences worth $334K as of Q1 2026.
Allen Capital Group bought 112 Gilead Sciences shares in Q1 2026, an estimated $15.7K.
Gilead Sciences made up 0.03% of Allen Capital Group's portfolio in Q1 2026, its #225 holding.
Allen Capital Group first reported a position in Gilead Sciences in Q2 2020 and has held it in 9 quarters since.
Allen Capital Group's Gilead Sciences position peaked at $649K in Q2 2020.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Allen Capital Group's 13F filing for Q1 2026, filed 27 May 2026.